Article Type
Changed
Mon, 09/18/2017 - 15:35
Display Headline
Emergency contraception

To the Editor: In her recent overview of emergency contraception (November 2012),1 Dr. Batur wrote that emergency contraception with levonorgestrel (Plan B One-Step) or combined estrogen-progestin-based methods does not cause abortion, noting that it is “unlikely to affect the ability of the embryo to attach to the endometrium.”1 We disagree. We consider any interruption of human development after fertilization to be abortion (ie, abortifacient).

Recently, Noé et al2 found that levonorgestrel was 100% effective in stopping clinical pregnancy when given 1 or 2 days before ovulation. However, previously, Croxatto et al3 noted (through ultrasonography) that levonorgestrel allowed ovulation 88% of the time when given 1 or 2 days before ovulation. Since levonorgestrel’s efficacy is significantly higher than its ability to inhibit ovulation on these days, another mechanism of action must be operant when ovulation does occur, that is, the other 88% of the time. A non-contraceptive action is the most likely explanation by default since the other main effect (ie, thickening of cervical mucus) likely plays little role if levonorgestrel is taken several hours after sexual activity.

Dr. Batur states that levonorgestrel is not an abortion pill because it serves “to enhance the progesterone effect”1 on the endometrium; however, it causes menstrual bleeding in about 15% of women taking it within 7 days.4 In addition, Kesserü et al5 noted that the intrauterine pH rose to more than 9 when a low dose was given. This is a 10-fold increase in alkalinity above the normal uterine pH. The pH within the fallopian tubes was not measured, but if a similar rise in pH occurred, it could easily explain how early embryos might die from levonorgestrel.

The medical literature cited above is consistent with the manufacturer’s claim that levonorgestrel “may inhibit implantation,” 6 and with the American Congress of Obstetricians and Gynecologists’ statement that “prevention of implantation may be a secondary mechanism of action.”7 Physicians and patients should be aware of this important ethical and clinical point.

References
  1. Batur P. Emergency contraception: Separating fact from fiction. Clev Clin J Med 2012; 79:771–776.
  2. Noé G, Croxatto HB, Salvatierra AM, et al. Contraceptive efficacy of emergency contraception with levonorgestrel given before or after ovulation. Contraception 2011; 84:486–492.
  3. Croxatto HB, Brache V, Pavez M, et al. Pituitary-ovarian function following the standard levonorgestrel emergency contraceptive dose or a single 0.75-mg dose given on the days preceding ovulation. Contraception 2004; 70:442–450.
  4. Gainer E, Kenfack B, Mboudou E, Doh AS, Bouyer J. Menstrual bleeding patterns following levonorgestrel emergency contraception. Contraception 2006; 74:118–124.
  5. Kesserü E, Garmendia F, Westphal N, Parada J. The hormonal and peripheral effects of d-norgestrel in postcoital contraception. Contraception 1974; 10:411–424.
  6. Teva Women’s Health Inc. Plan B One-Step product information. www.planbonestep.com/pdf/PlanBOneStep-FullProductInformation.pdf. Accessed January 10, 2013.
  7. American College of Obstetricians and Gynecologists. Frequently asked question 114. www.acog.org/~/media/For%20Patients/faz/114.pdf?dmc=1&ts=20121127T11830130312.
Article PDF
Author and Disclosure Information

Chris Kahlenborn, MD
Camp Hill, PA

Walter B. Severs, PhD, FCP
Hershey, PA

Issue
Cleveland Clinic Journal of Medicine - 80(3)
Publications
Topics
Page Number
185-186
Sections
Author and Disclosure Information

Chris Kahlenborn, MD
Camp Hill, PA

Walter B. Severs, PhD, FCP
Hershey, PA

Author and Disclosure Information

Chris Kahlenborn, MD
Camp Hill, PA

Walter B. Severs, PhD, FCP
Hershey, PA

Article PDF
Article PDF
Related Articles

To the Editor: In her recent overview of emergency contraception (November 2012),1 Dr. Batur wrote that emergency contraception with levonorgestrel (Plan B One-Step) or combined estrogen-progestin-based methods does not cause abortion, noting that it is “unlikely to affect the ability of the embryo to attach to the endometrium.”1 We disagree. We consider any interruption of human development after fertilization to be abortion (ie, abortifacient).

Recently, Noé et al2 found that levonorgestrel was 100% effective in stopping clinical pregnancy when given 1 or 2 days before ovulation. However, previously, Croxatto et al3 noted (through ultrasonography) that levonorgestrel allowed ovulation 88% of the time when given 1 or 2 days before ovulation. Since levonorgestrel’s efficacy is significantly higher than its ability to inhibit ovulation on these days, another mechanism of action must be operant when ovulation does occur, that is, the other 88% of the time. A non-contraceptive action is the most likely explanation by default since the other main effect (ie, thickening of cervical mucus) likely plays little role if levonorgestrel is taken several hours after sexual activity.

Dr. Batur states that levonorgestrel is not an abortion pill because it serves “to enhance the progesterone effect”1 on the endometrium; however, it causes menstrual bleeding in about 15% of women taking it within 7 days.4 In addition, Kesserü et al5 noted that the intrauterine pH rose to more than 9 when a low dose was given. This is a 10-fold increase in alkalinity above the normal uterine pH. The pH within the fallopian tubes was not measured, but if a similar rise in pH occurred, it could easily explain how early embryos might die from levonorgestrel.

The medical literature cited above is consistent with the manufacturer’s claim that levonorgestrel “may inhibit implantation,” 6 and with the American Congress of Obstetricians and Gynecologists’ statement that “prevention of implantation may be a secondary mechanism of action.”7 Physicians and patients should be aware of this important ethical and clinical point.

To the Editor: In her recent overview of emergency contraception (November 2012),1 Dr. Batur wrote that emergency contraception with levonorgestrel (Plan B One-Step) or combined estrogen-progestin-based methods does not cause abortion, noting that it is “unlikely to affect the ability of the embryo to attach to the endometrium.”1 We disagree. We consider any interruption of human development after fertilization to be abortion (ie, abortifacient).

Recently, Noé et al2 found that levonorgestrel was 100% effective in stopping clinical pregnancy when given 1 or 2 days before ovulation. However, previously, Croxatto et al3 noted (through ultrasonography) that levonorgestrel allowed ovulation 88% of the time when given 1 or 2 days before ovulation. Since levonorgestrel’s efficacy is significantly higher than its ability to inhibit ovulation on these days, another mechanism of action must be operant when ovulation does occur, that is, the other 88% of the time. A non-contraceptive action is the most likely explanation by default since the other main effect (ie, thickening of cervical mucus) likely plays little role if levonorgestrel is taken several hours after sexual activity.

Dr. Batur states that levonorgestrel is not an abortion pill because it serves “to enhance the progesterone effect”1 on the endometrium; however, it causes menstrual bleeding in about 15% of women taking it within 7 days.4 In addition, Kesserü et al5 noted that the intrauterine pH rose to more than 9 when a low dose was given. This is a 10-fold increase in alkalinity above the normal uterine pH. The pH within the fallopian tubes was not measured, but if a similar rise in pH occurred, it could easily explain how early embryos might die from levonorgestrel.

The medical literature cited above is consistent with the manufacturer’s claim that levonorgestrel “may inhibit implantation,” 6 and with the American Congress of Obstetricians and Gynecologists’ statement that “prevention of implantation may be a secondary mechanism of action.”7 Physicians and patients should be aware of this important ethical and clinical point.

References
  1. Batur P. Emergency contraception: Separating fact from fiction. Clev Clin J Med 2012; 79:771–776.
  2. Noé G, Croxatto HB, Salvatierra AM, et al. Contraceptive efficacy of emergency contraception with levonorgestrel given before or after ovulation. Contraception 2011; 84:486–492.
  3. Croxatto HB, Brache V, Pavez M, et al. Pituitary-ovarian function following the standard levonorgestrel emergency contraceptive dose or a single 0.75-mg dose given on the days preceding ovulation. Contraception 2004; 70:442–450.
  4. Gainer E, Kenfack B, Mboudou E, Doh AS, Bouyer J. Menstrual bleeding patterns following levonorgestrel emergency contraception. Contraception 2006; 74:118–124.
  5. Kesserü E, Garmendia F, Westphal N, Parada J. The hormonal and peripheral effects of d-norgestrel in postcoital contraception. Contraception 1974; 10:411–424.
  6. Teva Women’s Health Inc. Plan B One-Step product information. www.planbonestep.com/pdf/PlanBOneStep-FullProductInformation.pdf. Accessed January 10, 2013.
  7. American College of Obstetricians and Gynecologists. Frequently asked question 114. www.acog.org/~/media/For%20Patients/faz/114.pdf?dmc=1&ts=20121127T11830130312.
References
  1. Batur P. Emergency contraception: Separating fact from fiction. Clev Clin J Med 2012; 79:771–776.
  2. Noé G, Croxatto HB, Salvatierra AM, et al. Contraceptive efficacy of emergency contraception with levonorgestrel given before or after ovulation. Contraception 2011; 84:486–492.
  3. Croxatto HB, Brache V, Pavez M, et al. Pituitary-ovarian function following the standard levonorgestrel emergency contraceptive dose or a single 0.75-mg dose given on the days preceding ovulation. Contraception 2004; 70:442–450.
  4. Gainer E, Kenfack B, Mboudou E, Doh AS, Bouyer J. Menstrual bleeding patterns following levonorgestrel emergency contraception. Contraception 2006; 74:118–124.
  5. Kesserü E, Garmendia F, Westphal N, Parada J. The hormonal and peripheral effects of d-norgestrel in postcoital contraception. Contraception 1974; 10:411–424.
  6. Teva Women’s Health Inc. Plan B One-Step product information. www.planbonestep.com/pdf/PlanBOneStep-FullProductInformation.pdf. Accessed January 10, 2013.
  7. American College of Obstetricians and Gynecologists. Frequently asked question 114. www.acog.org/~/media/For%20Patients/faz/114.pdf?dmc=1&ts=20121127T11830130312.
Issue
Cleveland Clinic Journal of Medicine - 80(3)
Issue
Cleveland Clinic Journal of Medicine - 80(3)
Page Number
185-186
Page Number
185-186
Publications
Publications
Topics
Article Type
Display Headline
Emergency contraception
Display Headline
Emergency contraception
Sections
Disallow All Ads
Alternative CME
Article PDF Media